OnDemand
The Role of Icosapent Ethyl for CV Risk Reduction
  • Detail & Program Access
  • Overview & Objectives
  • Credit Eligibility
  • Faculty
  • Agenda
  • Program Materials
  • Funding Support
CLICK HERE TO VIEW THE VIDEO

Program Access and Details:

Program Length:
60 minutes

Resources:
DOWNLOADABLE SLIDES. View the Program Materials tab for more information.

Credits:
This program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.

Target Audience:
Family physicians, cardiovascular specialists, and allied health professionals

program advertising tile
CLICK HERE TO VIEW THE VIDEO

Program Access and Details:

Program Length:
60 minutes

Resources:
DOWNLOADABLE SLIDES. View the Program Materials tab for more information.

Credits:
This program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.

Target Audience:
Family physicians, cardiovascular specialists, and allied health professionals

program advertising tile

Perspectives from primary care, diabetology and cardiology.

Learning Objectives:

  • To review the role of serum triglycerides as a risk marker vs. a risk factor
  • To differentiate icosapent ethyl from standard fish oils
  • To best apply the findings from the REDUCE-IT study to clinical practice

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

 

Milan Gupta
MD, FRCPC, FCCS, CPC(HC)
Brampton, ON
David C. W. Lau
MD, PhD, FRCPC
Calgary, AB
Richard Ward
MD, CCFP, FCFP
Calgary, AB
Program Chapter
Are serum triglycerides a risk factor?
Do fish oils reduce CV risk?
How does icosapent ethyl differ from fish oils?
What are the main results of the REDUCE-IT study?
What is the mechanism of benefit?
How should we use icosapent ethyl in our practices?

Program slides:

This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization.  A PDF copy of the slides from this program are available for CCRN members from the CCRN website. Click the link below to be directed to the Resource Library.

Access CCRN Member Resource Library.

CCRN sm

This program was developed by the Canadian Collaborative Research Network and made possible through an educational grant from HLS Therapeutics Canada.

HLS Therapeutics | Clinical Trial Statistical Analysis, Study ...

© 2020-2021 MDLearn, All Rights are Reserved